What is the treatment for active Bartonella (Bartonellosis) infection?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 2, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

The treatment of active Bartonella infection typically involves antibiotic therapy with azithromycin 500mg on day one followed by 250mg daily for 5 days as the first-line option, as supported by a double-blind placebo-controlled study 1.

Key Considerations

  • The choice of antibiotic should be based on the severity of the infection and the patient's immune status.
  • For more severe infections or in immunocompromised patients, combination therapy may be necessary, often adding rifampin to the azithromycin regimen.
  • Alternative antibiotics include doxycycline, ciprofloxacin, or trimethoprim-sulfamethoxazole (TMP-SMX), all typically for 2-4 weeks depending on clinical response.
  • For Bartonella endocarditis or severe systemic disease, intravenous therapy with gentamicin may be combined with oral azithromycin for a total of 6 weeks, as recommended by guidelines for the management of patients with valvular heart disease 1.

Treatment Approach

  • Patients should be monitored for symptom improvement, and follow-up testing may be necessary to confirm clearance of the infection.
  • Bartonella bacteria can establish intracellular infections, which is why antibiotics with good intracellular penetration like azithromycin are preferred.
  • Treatment should be adjusted based on clinical response, with longer durations needed for immunocompromised patients or those with complications like endocarditis or neuroretinitis.

Important Considerations

  • The diagnosis of Bartonella infections may be difficult because the organism is fastidious and difficult to grow in culture, and serological testing may show cross-reactivity between different species of Bartonella 1.
  • A positive Warthin-Starry silver stain of infected lymph node tissue is useful to confirm the diagnosis, although it cannot differentiate species of Bartonella 1.

From the FDA Drug Label

Bartonellosis due to Bartonella bacilliformis. The treatment of active Bartonella infection is doxycycline (PO), as it is indicated for the treatment of Bartonellosis caused by Bartonella bacilliformis 2.

  • Key points:
    • Doxycycline is the recommended treatment
    • Bartonella bacilliformis is the specific species mentioned in the drug label
    • No other Bartonella species are mentioned in the label.

From the Research

Treatment Options for Active Bartonella Infection

The treatment of active Bartonella infection, also known as bartonellosis, depends on the severity of the disease and the patient's immune status.

  • For patients with Bartonella lymphadenopathy, antibiotics do not significantly affect the cure rate 3.
  • Patients with Bartonella spp. bacteraemia should be treated with gentamicin and doxycycline, while chloramphenicol has been proposed for the treatment of B. bacilliformis bacteraemia 4.
  • Gentamicin in combination with doxycycline is considered the best treatment regimen for endocarditis 4.
  • Erythromycin is the first-line antibiotic therapy for the treatment of angioproliferative lesions 4.
  • Rifampicin or streptomycin can be used to treat verruga peruana 4.

Antibiotic Susceptibility

The antibiotic susceptibility of Bartonella spp. can vary depending on the growth medium and intracellular environment.

  • In the standard insect media, none of the antibiotics tested were effective in inhibiting the growth of Bartonella sp. 5.
  • In the BAPGM enrichment media, all antibiotics tested had minimum inhibitory concentrations (MICs) below 0.5 µg/mL 5.
  • Azlocillin was the most potent antibiotic, with a MIC of 0.01 µg/mL 5.
  • When Bartonella was tested under intracellular growth conditions, none of the antibiotics were efficacious singly, but growth inhibition was observed when azlocillin and azithromycin were combined 5.

Emerging Treatment Options

Recent studies have identified FDA-approved drugs with activity against stationary phase Bartonella henselae.

  • These include pyrvinium pamoate, daptomycin, methylene blue, azole drugs, aminoglycosides, and others 6.
  • These drugs have shown higher activity against stationary phase B. henselae than the current frontline antibiotic erythromycin 6.
  • Further research is needed to develop more effective treatments for persistent Bartonella infections.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Treatment outcomes of human bartonellosis: a systematic review and meta-analysis.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2013

Research

Pathogenicity and treatment of Bartonella infections.

International journal of antimicrobial agents, 2014

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.